Related Experiment Video
Updated: Sep 17, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the
Fernando Bril1,2, Parameshwara Bolla1, Ky Huynh1
1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
Objective:
We aimed to evaluate recent changes in the prevalence of steatotic liver disease, its subtypes, and liver fibrosis among US adults with and without diabetes between 2017-2020 and 2021-2023.
Research Design And Methods:
In this serial cross-sectional study, we assessed adults aged ≥18 years with complete vibration-controlled transient elastography (Fibroscan®) data from the National Health and Nutrition Examination Surveys from 2017-2020 and 2021-2023. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined as liver steatosis in the presence of 1 cardiometabolic risk factor.
Results:
A total of 13 153 adults (n = 7683 from 2017-2020; n = 5470 from 2021-2023) were included. The prevalence of MASLD significantly decreased from 37.6% to 32.5% in this period (P = .001), and this was particularly noticeable among individuals with prediabetes (from 49.1% to 41.8%; P = .002) or diabetes (from 69.4% to 61.4%; P = .013). Despite the lower prevalence of MASLD, the prevalence of clinically significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4) significantly increased in this period, especially among individuals with diabetes. Of note, among individuals with diabetes, clinically significant fibrosis reached 27.4% and cirrhosis 10.2% in 2021-2023. Alcohol-related liver disease also increased from 1.0% to 1.7% (P = .037) in the overall population, with similar increases in prediabetes and diabetes.
Conclusion:
Despite the evidence of a decline in MASLD prevalence, rates of liver fibrosis and cirrhosis are rising, especially in individuals with diabetes. This underscores the need for improved screening of liver fibrosis, early initiation of effective pharmacological therapies, and aggressive management of related cardiometabolic conditions in individuals with diabetes.
Related Concept Videos
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Type 2 and Gestational
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...